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Photoacoustic Computed Tomography of Breast Cancer in
Response to Neoadjuvant Chemotherapy
Li Lin, Xin Tong, Peng Hu, Marta Invernizzi, Lily Lai,* and Lihong V. Wang*
Neoadjuvant chemotherapy (NAC) has contributed to improving breast cancer
outcomes, and it would ideally reduce the need for definitive breast surgery in
patients who have no residual cancer after NAC treatment. However, there is
no reliable noninvasive imaging modality accepted as the routine method to
assess response to NAC. Because of the inability to detect complete response,
post-NAC surgery remains the standard of care. To overcome this limitation, a
single-breath-hold photoacoustic computed tomography (SBH-PACT) system
is developed to provide contrast similar to that of contrast-enhanced magnetic
resonance imaging, but with much higher spatial and temporal resolution and
without injection of contrast chemicals. SBH-PACT images breast cancer
patients at three time points: before, during, and after NAC. The analysis of
tumor size, blood vascular density, and irregularity in the distribution and
morphology of the blood vessels on SBH-PACT accurately identifies response
to NAC as confirmed by the histopathological diagnosis. SBH-PACT shows its
near-term potential as a diagnostic tool for assessing breast cancer response
to systemic treatment by noninvasively measuring the changes in
cancer-associated angiogenesis. Further development of SBH-PACT may also
enable serial imaging, rather than the use of current invasive biopsies, to
diagnose and follow indeterminate breast lesions.
1. Introduction
Although breast cancer remains the second leading cause of fe-
male cancer deaths in the United States, significant progress has
been made in improving overall survival.[1] The development and
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increased use of effective and directed sys-
temic therapy based on biological charac-
terization of the subtypes of breast cancer
have directly contributed to improvement in
survival outcomes.[2–4] Specifically, neoad-
juvant chemotherapy (NAC), systemic ther-
apy that is given before surgery, has con-
tributed to improved cancer outcomes in
breast cancer patients by increasing the
likelihood of breast conservation[5,6] and
by providing patients with important prog-
nostic information based on response to
treatment.[7,8] Confirmation of cancer re-
sponse to NAC is associated with improved
disease-free and overall survival.[8] In addi-
tion, evaluation of breast cancer response
to NAC assists in drug development.[9,10]
Lastly, exceptional responders to NAC may
have eradication of their breast cancers. In
these exceptional responders, the risk of
breast cancer recurrence is low with as-
sociated excellent 5-year relapse free sur-
vival of 95% and 94% in patients with
HER2+ and Triple Negative breast can-
cers, respectively.[11] These findings argue
against the need for definitive surgery and
directly challenge the current paradigm of surgical resection es-
tablished for solid tumors. Indeed, interest in the elimination of
surgery in patients with exceptional response has resulted in ac-
tive prospective clinical trials to evaluate the outcomes in women
who receive NAC and do not undergo definitive surgery.[12]
At present, there is no reliable noninvasive imaging modal-
ity clinically accepted to determine complete cancer response to
NAC. Consequently, response of the cancer to treatment is di-
agnosed only after the breast tissue is surgically removed. Cur-
rent noninvasive clinical methods to monitor cancer’s response
to NAC include clinical breast examination, mammography, ul-
trasonography, and magnetic resonance imaging (MRI). These
methods depend on cancer morphology and size measurements,
which may not change despite the cancer’s response to ther-
apy. Furthermore, therapy-induced fibrosis often impedes these
modalities from accurately monitoring response to NAC.[13]
The ability to identify the optimal time point to differentiate re-
sponders from non-responders would contribute greatly to clin-
ical management of the breast cancer patients. Recent studies
have begun to examine the functional and anatomical changes
in cancer to improve the ability to assess response to therapy.
These studies utilized fluorothymidine positron emission tomog-
raphy (PET),[14] contrast-enhanced MRI (CE-MRI) with vascular
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enhancement,[15] and diffuse optical imaging (DOI).[16] The early
results of these investigational imaging methods highlight the
potential for metabolic and hemodynamic measurements. How-
ever, both PET and CE-MRI require the use of exogenous contrast
agents and local facilities to either handle radioactive materials or
a strong magnetic environment. These issues, as well as the du-
ration of the imaging studies, are barriers against frequent and
timely evaluations of patients treated with NAC. DOI can provide
frequent label-free monitoring of patients. However, the spatial
resolution of DOI is limited,[17] diminishing the potential of this
modality for imminent clinical use. Therefore, there remains a
critical need to develop imaging technology to improve on the
assessment of breast cancer treated with NAC.
Photoacoustic computed tomography (PACT) combines the
functional optical contrast of DOI and the high spatial resolution
of ultrasonography, without speckle artifacts.[18] The rich contrast
provided by optical absorption, which is related to various in-
trinsic and extrinsic contrast origins, enables PACT to perform
structural, functional, and molecular imaging.[19] When a short-
pulsed laser irradiates biological tissues safely, wideband ultra-
sonic waves (referred to as photoacoustic waves) are induced as
a result of transient thermoelastic expansion. The photoacoustic
(PA) waves are then measured by ultrasonic transducers around
the tissue and are used to reconstruct the optical absorption dis-
tribution in the tissue. At 1064 nm, which is the fundamental
wavelength of Nd:YAG lasers, the 1/e optical attenuation coeffi-
cient for an average breast is around 0.9 cm−1,[20] which is slightly
higher than that for X-rays (0.5–0.8 cm−1).[21] However, the opti-
cal contrast of soft tissue is much higher than X-ray contrast.[22]
For breast imaging, preliminary studies have shown that PACT
can exploit its advantages to the fullest, offering high spatial and
temporal resolution at sufficient depths,[23,24] using nonionizing
radiation.
The use of PACT to assess response to NAC in breast can-
cer has been reported.[25–27] However, previous PACT studies
were unable to image detailed angiographic structures (i.e., in-
dividual blood vessels) due to system limitations such as insuf-
ficient spatial sampling rate and limited detection angle, thus
limiting their accuracy and reliability. For example, the breast
could be deformed differently during each imaging session, af-
fecting the light fluence in the tissue to be inconsistent and un-
predictable. As such, without the ability to reveal detailed breast
anatomy, the quantitative measurements (e.g., total hemoglobin
concentration) requiring prior knowledge of the optical distribu-
tion are unreliable. Recently, we developed a single-breath-hold
PACT (SBH-PACT) system capable of detailing angiographic
structures of the whole breast within a single breath hold of 15
s. The imaging completed by SBH-PACT clearly delineates tu-
mor angiogenesis,[23] a process that has been described as a hall-
mark of cancer growth and metastasis.[28–30] In addition, an in-
crease in vascular endothelial growth factor expression has been
associated with impaired response to chemotherapy.[31,32] Taken
together, the ability to image and analyze angiogenesis has the
potential to detect changes in the breast cancer from disease pro-
gression or from response to treatment. In addition, since angio-
genesis precedes transformation of mammary hyperplasia to ma-
lignancy, monitoring tumor-associated microvasculature change
over time may assist in early detection and diagnosis of breast
cancer in patients with abnormal mammograms. Use of serial
noninvasive imaging such as SBH-PACT may lead to a more
streamlined and accurate workup of indeterminate lesions and
obviate the need for invasive diagnostic biopsies.
To better assess the ability of SBH-PACT to determine breast
cancer response to NAC, we imaged three breast cancer patients
treated with NAC at three time points: before, during, and after
NAC. We segmented the boundaries of the cancers and quan-
tified the changes in cancer size and the density, entropy, and
morphological irregularity of the cancer blood vessels. These
analyses from the SBH-PACT images were compared with the
histopathological results, treated as ground truth, of the resected
breast specimen. In this report, we describe our initial experi-
ence with SBH-PACT and demonstrate that SBH-PACT, compa-
rable to a contrast-free, high-speed, and high-resolution version
of CE-MRI, is capable of providing details and capturing changes
associated with response of breast cancer to NAC.
2. Results
2.1. Evaluation of the SBH-PACT System with a
Breast-Mimicking Phantom
As shown in Figure 1a, a patient bed is placed above the SBH-
PACT system with minimal separation (Figure S1, Supporting
Information). Laser light is expanded into a homogenized cir-
cular beam and directed upward to illuminate the breast that
is slightly compressed against the chest wall. A full-ring ultra-
sonic transducer array with an in-plane panoramic view detects
photoacoustic waves around the breast. A linear stage motorizes
the transducer array to scan the breast elevationally. By scanning
within a single breath hold of 15 s, SBH-PACT can reveal detailed
angiographic structures of the entire breast, visualizing vascula-
tures down to an apparent vascular diameter of 258 µm.[23]
Before imaging breast cancer patients, we first assessed the
system’s sensitivity to detecting small abnormalities in the breast
by imaging a breast-mimicking phantom (Figure 1b), which con-
sisted of clear agarose (3%), black acrylic ink (0.0125%), and
20% intralipid (3.6%).[33] We used 3D-printed molds to make the
phantom with embedded tumors (Figure S2, Supporting Infor-
mation). Seven tumor phantoms were embedded in the breast
phantom at a depth of 2 cm. The diameters of the tumors were
designed to be 1, 1.5, 2, 2.5, 3, and 3.5 mm respectively. The
absorption coefficient of the tumors (𝜇a = 0.105 cm−1 ) was 2.1
times that of the breast phantom (𝜇a = 0.05 cm−1 ).[20,34] The re-
duced scattering coefficient 𝜇′s of the phantoms was 5 cm
−1 at
1064 nm.[20] In the phantom image (Figure 1c), the tumors near
the side appear larger than what we designed, possibly due to dif-
fusion of the ink. However, the system is sufficiently sensitive to
detect a 1 mm-diameter tumor (near the center), which appears
to be the correct size.
2.2. Pilot Clinical SBH-PACT Studies with Patient Reported
Outcomes
The primary objectives of this study are to assess the use of SBH-
PACT in women with breast cancer treated with NAC and to de-
velop quantitative measurements to detect responses in the NAC-
treated breast cancers. Four patients diagnosed with breast can-
cer requiring NAC consented and accrued to the clinical study.
Adv. Sci. 2021, 8, 2003396 © 2021 The Authors. Advanced Science published by Wiley-VCH GmbH2003396 (2 of 10)
www.advancedsciencenews.com www.advancedscience.com
Figure 1. Schematic of the SBH-PACT and breast phantom imaging. a) Perspective cut-away view of the SBH-PACT breast imaging system. DAQ,
data acquisition module; Pre-amp, preamplifiers. b) Sketch of the breast-mimicking phantom. c) Maximum-amplitude-projection (MAP) of the breast
phantom image acquired by SBH-PACT, which revealed the smallest tumor phantom (1-mm diameter). The bright dots in the image background were
caused by air bubbles embedded in the phantom.
The clinical study was closed after the first visit of the fourth pa-
tient due to the coronavirus pandemic (Table S1, Supporting In-
formation). However, prior to the study closure, we completed
nine SBH-PACT imaging sessions in three patients (n = 3). The
patients were imaged at three time points (Figure S3, Supporting
Information): (T1) prior to initiation of NAC; (T2) during NAC;
and (T3) after completion of NAC and before surgery. The im-
ages were compared with other diagnostic imaging acquired as
part of standard clinical care (such as mammogram and MRI)
as well as with the final histopathological report of the resected
breast tissue. All SBH-PACT images were reconstructed and pro-
cessed without prior knowledge of clinical images or pathological
response.
At the end of each session, the patient completed a self-
administered survey developed to assess the user experience of
the SBH-PACT (Figure S4, Supporting Information). The pa-
tients reported that SBH-PACT was easier than MRI and mam-
mography and comparable to breast ultrasonography. Among the
three patients that completed three visits, two patients had in-
complete response with solid masses left after the NAC as pal-
pated on clinical exam or imaged on MRI. The other patient had
complete clinical response with no definable mass on physical
exam and on MRI.
2.3. SBH-PACT of Breast Cancer Treated with NAC
Figure 2 shows SBH-PACT breast images of one patient at T1, T2,
and T3 time points. We listed the color-encoded depth-resolved
angiograms of the unaffected (Figure 2a) and affected breasts
(Figure 2c). The contralateral images of the unaffected breast
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Figure 2. Breast images of a patient treated with NAC. a) Depth-encoded angiograms of the unaffected (right) breast acquired by SBH-PACT at three
time points. b) Vessel density maps overlaid on the maximum-amplitude-projections (MAPs) of the breast images in (a). c) Depth-encoded angiograms
of the affected (left) breast of the patient. d) Vessel density maps overlaid on the MAPs of the images in (c). Regions with higher vascular densities are
highlighted.
serve as controls in which angiographic structures were not sig-
nificantly changed by the NAC.
The cancer appears as a region with higher density blood ves-
sels on the SBH-PACT images. To automatically highlight such
regions in the breast, we extracted the vessel skeletons and gen-
erated vessel density maps for each image (Figure 2b,d). The re-
gions with the highest vessel density correspond to the location
of the cancer (Figure 2d). The images clearly show the shrink-
age of the lesion with NAC although the patient did not have a
complete response. The regions with higher vessel density out-
side the pathologically-confirmed cancer could be false positives,
which, however, might indicate early-state lesions that have not
been clinically diagnosed.[35]
In the unaffected breasts, we also observed areas with in-
creased vessel densities that were unaccounted for in con-
ventional breast imaging (Figure S5, Supporting Information).
Given SBH-PACT’s high sensitivity to microvasculature, the ar-
eas with abnormally high vessel densities may represent early
neoplastic changes in the breast not detectable by current imag-
ing including MRI. Despite advances in breast imaging technol-
ogy such as CE-MRI, there remains up to an 11.3% rate of an oc-
cult breast cancers, identified only in the resected specimen.[36]
We anticipate that SBH-PACT may improve on detection of early
and image-occult breast lesions. However, it remains possible
that these areas of increased vessel density may represent arti-
fact or benign changes in the breast. In unaffected breasts, the
enhancement of the regions with higher vessel densities can be
eliminated by using a higher vessel density threshold (e.g., 2.5
mm−2) and/or rejecting the regions smaller than a certain area
(e.g., 4 mm2).
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Figure 3. SBH-PACT images of the other two patients treated with NAC.
a) Angiograms of Patient 2 who had a partial response to NAC. Close-up
views of the cancer-affected area are shown from T1 to T3 in the region
outlined by yellow dashed boxes (bottom right corner of figure). Breast
cancer is identified by yellow arrows. Prominent common blood vessels
in T1 and T2 images are marked by magenta arrow lines. b) Angiograms
of Patient 3 who had a complete clinical response to NAC. Angiogenesis
associated with the cancer was not detected at T3.
Figure 3a shows another case (Patient 2) with partial response
in breast cancer. Angiogenesis near the cancer region was still
apparent after NAC at T3. In addition, SBH-PACT also iden-
tified a patient with complete clinical response to NAC (Fig-
ure 3b, Patient 3). For this patient, cancer-associated angiogen-
esis decreased at T2 and almost disappeared at T3, consistent
with the near pathological complete response confirmed by the
histopathological examination (Table S2, Supporting Informa-
tion).
2.4. Breast Cancer Segmentation Based on Blood Vascular
Irregularity
In addition to blood vessel density that is observed directly, we
also extracted other characteristics of the blood vasculature in
the breast. We determined that the cancer-associated vasculature
tend to lack order, i.e., have greater irregularity in distribution
and morphology, when compared to healthy breast tissue. To eval-
uate the randomness of the vascular distribution, we calculated
entropy maps of the PACT images (Figure 4a) to quantify PA am-
plitude fluctuations. Cancers and vessel boundaries have shown
higher entropy because cancer-associated angiogenesis induces
more fluctuation than normal breast tissues and blood vessel
boundaries have abrupt PA amplitude changes. Since the vascu-
lature in the healthy tissue tends to be smoother and more direc-
tional, we further quantified the irregularity of the vascular mor-
phology (i.e., anisotropy) and then used it to weight the entropy
map, suppressing the structures in healthy tissues (Figure 4b).
To automatically encircle the breast cancer, we developed an
algorithm for cancer segmentation. We binarized the anisotropy-
weighted entropy maps with a threshold of each whole-breast’s
average plus 1.4 times the standard deviation. This threshold was
chosen so that the segmented tumor sizes were similar to those
measured by breast MRI. We then isolated the contiguous re-
gion with the largest pixel number to acquire the cancer mask
(Figure 4c). Using the cancer masks in SBH-PACT images, we
measured the cancers’ dimensions.
In addition to cancer segmentation, anisotropy-weighted en-
tropy maps were also used to modulate the original angiograms
(Figure 5a). Since the breasts were compressed differently during
PACT and MRI scanning, we rotated the MRI images to a view
angle between the craniocaudal view and mediolateral view, so
that the relative positions of the tumor and major blood vessels
in the PACT images were similar to those in the MRI images. The
side-by-side comparison of the SBH-PACT and MRI images at T1
and T3 (Figure 5b) demonstrates concordance of the two imag-
ing modalities in detecting change in the cancer with treatment
and the partial response to NAC. However, only the SBH-PACT
images revealed the angiographic details of the response of the
cancer; the MRI images did not.
In SBH-PACT, the spatial resolution in the elevational di-
rection (5.6 mm) is much coarser than the in-plane resolution
(255 µm). Also, the blood vessels in the cancer-affected areas are
close together in the elevational direction (e.g., similar color in
Figure 2c). Therefore, we performed quantitative analysis on 2D
images that were produced by MAP along the elevational direc-
tion. Considering the relatively low blood volume in the breast,[37]
MAP along the elevational direction may capture most angio-
graphic structures in the breast. It would be more accurate to
measure the cancer’s characteristics in 3D space, which, however,
would require isotropic spatial resolution in 3D space.
2.5. Measurements of Breast Cancer Characteristics to Evaluate
Response to NAC
To quantitatively analyze the response of the cancer to NAC, we
defined a region of interest (ROI) as the cancer-affected area in
the T1 image and applied the same ROI on the coregistered im-
ages of T2 and T3. Figure 6 summarizes the cancers’ characteris-
tics we extracted from SBH-PACT images and used to determine
response to NAC. For each image, we quantified the cancer size,
blood vessel density, entropy, and anisotropy as measures of the
cancer response. The measurements of the cancer dimensions
(Figure 6a) in SBH-PACT images were comparable to those of
the clinical imaging modalities (i.e., mammography, ultrasonog-
raphy, and MRI) and agreed well with the histopathological di-
agnosis (Table S2, Supporting Information). The smallest cancer
identified as a solid mass on SBH-PACT was 0.8 cm × 0.6 cm ×
0.5 cm in Patient 3 at T2. We directly observed the decrease in
size of the cancers with NAC in serial SBH-PACT images of all
three patients.
Moreover, we observed noticeable decreases in the relative vas-
cular density (red columns in Figure 6b), entropy (Figure 6c),
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Figure 4. Breast cancer segmentation based on blood vascular irregularity. a) Entropy maps computed from the breast angiograms. b) Anisotropy-
weighted entropy maps, which suppress the structures in healthy tissues. c) Segmented maps of the cancer-affected area extracted from (b).
and anisotropy (Figure 6d) of the cancer with NAC. We imaged
the contralateral, unaffected breast of each patient for compari-
son. The same measurements were almost unchanged with NAC
in the unaffected breast (blue columns in Figure 6b–d). To de-
termine if these differences between the affected (ROI) and the
healthy breast tissues were significant, we applied a Welch’s (un-
equal variances) t-test to determine the p-values under the null
hypothesis that the mean values of parameters in the ROI are
not greater than those in the healthy breast tissues. For exam-
ple, in patient 3, the blood vessel measurements in the ROI and
the healthy tissue in the T1-image were different (p-value < 0.01).
However, after NAC, the blood vessel measurements in the T3-
image were not statistically significant, with a p-value > 0.1, sug-
gesting that the patient’s breast cancer may have had a complete
response to NAC. In comparison, the vessel measurements in the
ROI and healthy tissues of Patients 1 and 2 had significant statis-
tical differences (p < 0.05) across the T1–T3 images, suggesting
the cancers had a partial response to NAC.
The assessment of angiographic microvasculature provided a
reliable method to evaluate the anatomic changes of the cancer
with treatment. We also calculated the averaged PA amplitude
within the ROI and the healthy tissue in the same depth (Fig-
ure S6, Supporting Information), showing a decrease in the PA
amplitude ratio between the ROI and the healthy tissue over the
course of treatment. However, only assessing PA amplitude is
not reliable for diagnosis. For example, breast deformation dur-
ing each visit (T1, T2, and T3) affected optical fluence differently,
resulting in noticeable PA amplitude changes in the healthy tis-
sue during the treatment.
3. Discussion and Conclusion
In this study, we demonstrate the potential for SBH-PACT as a
diagnostic tool to assess breast cancer responses to chemother-
apy. SBH-PACT clearly depicts detailed angiographic structures
from the nipple to the chest wall and localizes the breast cancer
with the higher blood vessel density. Processing of the breast im-
ages based on vascular entropy and anisotropy further enhances
the ability to detect differences between normal breast tissue and
breast cancer with treatment and over serial images. Based on
these findings, we developed an algorithm for breast cancer seg-
mentation and quantified the cancer size, relative blood vessel
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Figure 5. Comparison of the images acquired by SBH-PACT and MRI. a)
SBH-PACT angiograms weighted by Figure 4b. b) MRI images of the same
breast with dynamic post contrast sequence acquired at T1 and T3 of the
NAC treatment. Correlated structures are marked by magenta arrow lines.
SBH-PACT reveals more angiographic details within a single breath hold
of 15 s.
density, entropy, and anisotropy as measures of response to NAC.
In addition, patient experience of this imaging modality was fa-
vorable, with feedback suggesting that SBH-PACT was comfort-
able and easier than other breast imaging tests.
We completed SBH-PACT imaging of the affected and unaf-
fected breast in three separate time points in three patients for
a total of nine imaging sessions. The clinical study was closed
by the Institutional Review Board at Caltech to protect patients
from unnecessary exposure during the coronavirus pandemic.
However, the aggregated data from the patients suggests that
SBH-PACT is sufficiently sensitive to capture the angiographic
changes in breast cancer during treatment.
The current imaging system can be further improved using a
laser with a higher pulse energy and repetition rate, which will
increase the signal-to-noise ratio to reveal greater clarity of struc-
tures previously obscured by the background noise. To reduce the
breast thickness for light to penetrate from the nipple to the chest
wall, our current system compresses the breast using a soft agar
pillow. This method could not fully confine the breast’s shape
during imaging, thus affecting the reproducibility of serial im-
ages. To better control for breast tissue deformation, SBH-PACT
can be equipped with breast holding cups made by a thin layer of
polymethylpentene (TPX) that has a similar acoustic impedance
to the breast tissue.[38] In addition to the improvements in the
imaging system, post-processing of the reconstructed images
could further improve imaging sensitivity, especially for the de-
tection of microscopic disease.[39–41] For example, Liu et al. pro-
duced high PA imaging sensitivity by using a multiscale vascular
enhancement filter[40] and deep learning method[41] to reveal de-
tailed structures in PA angiograms.
The clear imaging and accurate evaluation of breast tumor-
associated angiogenesis support further development of SBH-
PACT in breast imaging. Angiogenesis plays a central role in
breast cancer development, invasion, and metastasis. Until now,
measurements of angiogenesis have not been used in imag-
ing likely because of inability to accurately detect microvascular
changes. However, our study demonstrates the use of SBH-PACT
vascular measurements to assess response to treatment in breast
cancer. In addition, the ability to fully scan each breast within 15
s and without intravenous contrast or ionizing radiation further
support ongoing studies to advance this technology for clinical
use.
Other potential applications in breast cancer detection and
treatment include screening and surveillance. In addition to the
diagnosis of response to the NAC in breast cancer patients, imag-
ing and quantitatively measuring the angiographic environment
in the breast using SBH-PACT has the potential to assist as a
prognostic tool to determine relapse-free survival,[42] as a real-
time test of response in drug development,[43] and as an alterna-
tive to invasive biopsies for diagnosis.
4. Experimental Section
System Construction and Image Formation: In the SBH-PACT, a 1064-
nm laser beam from an Nd:YAG laser (LPY 7875-20, Litron Lasers, Ltd.)
was first expanded by an engineered diffuser (EDC-10, RPC Photonics,
Inc.) to form a circular light beam. The laser fluence (28 mJ cm−2) was
within the American National Standards Institutes (ANSI) safety limit
for laser exposure (50 mJ cm−2 at 1064 nm at a 20-Hz pulse repetition
rate).[44] To achieve 2D panoramic acoustic detection, a full-ring ultrasonic
transducer array is employed with 512 elements (Imasonic, Inc.; 220 mm
ring diameter; 2.25 MHz central frequency). The ultrasonic transducer ar-
ray was enclosed in an acrylic water tank for acoustic coupling to the
breast. Four sets of 128-channel preamplifiers (26 dB gain) and data acqui-
sition systems (SonixDAQ, Ultrasonix Medical ULC) were placed around
the water tank, amplifying and digitizing the PA signal. The data acquisi-
tion systems were configured to record PA signals within 100 µs after each
laser pulse excitation.
The universal back-projection (UBP) algorithm[45] was used to recon-
struct all images in this work. The ultrasonic transducer array scanned the
entire breast from the chest wall to the nipple, back-projecting the time-
domain PA signals at all elevational scanning steps into the 3D space.
SBH-PACT has an in-plane resolution of 255 µm and an elevational reso-
lution of 5.6 mm.[23] Each volumetric image was first reconstructed with
a voxel size of 1 mm in the elevational direction and 0.1 × 0.1 mm2 on
the horizontal plane. All the reconstructed images were further batch-
processed to improve contrast. A depth compensation (e0.6 × depth(cm))
method was first applied to enhance the PA amplitude in the deep
tissue. The compensated images were then denoised using sparse
4D transform-domain collaborative filtration.[46] Hessian-based Frangi
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Figure 6. Quantitative measurements of the tumors’ transformation during the NAC. Statistical data are presented as mean ± standard error; p-values
are calculated using one-tailed Welch’s (unequal variances) t-test. a) Measurements of tumor dimensions and volume. LA, long axis; SA, short axis. b)
Quantification of the relative blood vascular density in the ROI and healthy tissues. c) Quantification of the blood vascular entropy in the ROI and healthy
tissues. d) Quantification of the blood vascular anisotropy in the ROI and healthy tissues.
vesselness filtering[47] was then applied to the denoised images to en-
hance the contrast of blood vessels. Finally, the filtered images (self-
normalized) were then added with a weighting factor of 0.35 to the de-
noised images with a weighting factor of 0.65 and obtained the presented
images.
Standard Imaging Procedure: The human studies were completed un-
der institutional approval and oversight by both California Institute of
Technology (Committee for the Protection of Human Subjects, 18–0785)
and City of Hope National Medical Center (Institutional Review Board,
17 315). Breast imaging was performed in a dedicated human imaging
room installed with privacy curtains. Enrolled patients who were sched-
uled to undergo NAC treatment were imaged using SBH-PACT at 3 time
points: (T1) after the standard care work-up and the percutaneous biopsy,
but prior to initiation of neoadjuvant therapy; (T2) during neoadjuvant
therapy; and (T3) after completion of neoadjuvant therapy but prior to
surgery. The specific timing of the T2 imaging was set after 2 cycles of
chemotherapy (≈4–6 weeks after initiation).
Prior to imaging, the imaging bed and the imaging system were thor-
oughly sanitized using disinfecting wipes (Super Sani-Cloth germicidal
disposable wipe). The bed was covered by examining table paper dis-
carded after each use. During SBH-PACT imaging, a female study coor-
dinator assisted the patient in a private space enclosed by curtains. Other
researchers involved in the clinical studies operated the device outside the
private space. The study coordinator covered the patient’s nipples with
white nipple masks (3M micropore surgical paper tape), used to partially
block the light given the higher concentration of pigment at the nipple.
The patient was positioned prone, with one breast placed in the water tank
through a large aperture in the bedtop. The water tank was filled with pre-
heated clean water at a temperature of 35 °C.
At the end of each imaging session, the patient was asked to complete
a self-administered two-page survey. The survey required less than 5 min
to complete.
Measurement of the Relative Blood Vessel Density: To measure relative
blood vessel density, blood vessel skeletons were first extracted by gener-
ating vessel centerlines[23] from the MAP images. The vessel centerlines
were broken into independent vessels at junction points. Independent ves-
sels were then removed with lengths less than 3 pixels to reduce noise.
To generate the blood vessel density map, a 2 mm × 2 mm window was
scanned across the entire vessel skeleton image. The vessel density was
quantified as the number of vessels in the window divided by the window
area. The vessel density of the window area was then assigned to the win-
dow’s center pixel.[23] We name this parameter relative vessel density be-
cause the calculated density depends on the window size which, however,
has a minor effect on the p-values of the relative vessel density in t-tests.
Measurement of the Vascular Entropy and Anisotropy: To mitigate the
background noise and single-pixel artifacts, thresholding was first ap-
plied to the MAPs (2D matrix MPA) of the batch-processed images. The
threshold was selected as the maximum PA amplitude within the selected
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background (i.e., a region outside the breast). A 1 mm × 1 mm window
was then used to scan across every pixel in the image. For each image









where n denotes the number of discrete bins in the window, Pi denotes
the probability for a pixel to have value fallen in the ith bin. The acquired
entropy was then assigned to the center pixel of the window, forming an
entropy map Me (Figure 3A).
Similarly, to measure the vascular anisotropy, the MPA was scanned us-
ing the same window size. For each subset MsubPA , the M
sub
PA was rotated
from 0° to 180°, with a step size of 10°. At each rotation angle 𝜃, the sin-
gular value decomposition (SVD) of the rotated MsubPA was calculated, ac-








where ∑(𝜃) denotes the corresponding diagonal singular value matrix and∑
11(𝜃) represents the element in the first column of the first row, and
tr[∑(𝜃)] denotes as the trace of matrix ∑(𝜃). After rotating the MsubPA over
180°, the directionality D was calculated within the window defined as
D = max
𝜃
NSVD (𝜃) − min
𝜃
NSVD (𝜃) (3)
The smooth and straight blood vessels in the image tend to have a
higher directionality value. To make the measurement more intuitively
meaningful, anisotropy as A = 1
D+𝜀 was further defined, where 𝜖 ≈ 0.01
is the regularization term to bound the reciprocal. In each window, the
entropy H was weighed with A to suppress the blood vasculatures in the
healthy tissue





where E is the anisotropy-weighted entropy. The coefficient k was set to
30. Similarly, E was assigned within each window to the window’s center
pixel, generating the anisotropy-weighted entropy map Mae (Figure 3B).
An automatic tumor segmentation algorithm was developed to assist
evaluating the tumors’ changes during the NAC treatment. Thresholding
was first applied to Mae and then binarized it. The contiguous region was
then isolated with the largest area to segment the tumor-affected region
(e.g., Figure 3C).
In addition, the MAP image MPA was modulated with Mae to acquire
image Mf (Figure 3D) with enhanced lesions and detailed angiographic
structures
Mf = (Mae + 𝛽) × MPA (5)
where 𝛽 ≈ 0.07 is a background constant to maintain the information in
the healthy tissue.
Standard of Care Work-Up, Neoadjuvant Chemotherapy, and Pathologic
Diagnosis: All the human experiments followed protocols approved by
the Institutional Review Boards of California Institute of Technology (Pro-
tocol 18–0785) and City of Hope National Medical Center (Protocol
17 315). Patients for the clinical study were identified and referred by treat-
ing oncologists at the City of Hope National Comprehensive Cancer Cen-
ter. Diagnosis of the breast cancer and work up included combinations
of mammography, ultrasound, MRI, and breast biopsies. The decision to
treat with NAC and the regimen used was at the discretion of the medi-
cal oncologist and based on current treatment guidelines. The post-NAC
imaging and definitive surgery were decided by the physicians based on
patient preference, response to therapy, and projected cancer outcomes.
SBH-PACT was performed in a dedicated human breast imaging room
at Caltech. After verbally agreeing to participate in the study, the patient
signed the informed consent form, formally verifying her understanding
of the experiment and agreement to participate. Each patient underwent
three SBH-PACT sessions. At the end of each imaging session, a survey
was completed by the patient. All cases were reviewed following receipt of
the final pathology report to determine imaging-pathologic correlation.
Statistical Analysis: To examine the significance of difference between
the healthy tissue and the tumors, a one-tailed Welch’s (unequal vari-
ances) t-test was performed on the healthy and cancerous areas as se-
lected by the binary masks. A sliding window was further applied for
relative vessel density, entropy, and anisotropy calculations. The sliding
windos have no overlap to ensure numerical indepenence for statistical
analysis.
The mean value ± standard error of each image is shown in Figure 6,
and the null hypothesis H0 for each t-test is that the tumor region has
less or equal population means as the corresponding healthy tissues. The
results for the one-tailed tests are shown in Figure 6 as p-values. Accord-
ingly, the p-values are generally less than 0.05, indicating a rejection of H0
at the 5% significance level. In contrast, the p-values for Patient 3 visit 3
were typically larger than 0.1. All statistical analysis was done based on the
2D maps via MATLAB function “ttest2.”
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